Impact of high dose versus low dose atorvastatin on contrast induced nephropathy in diabetic patients with acute coronary syndrome undergoing early percutaneous coronary intervention

Egyptian Heart Journal

Volumn 67, Issue 4, 2015, Pages 329-336

  Galal, Haitham ^a   Nammas, Wael ^a   Samir, Ayman ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Atorvastatin; Contrast induced nephropathy; Diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UREA;

ACUTE CORONARY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES CONTROL; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE COMPARISON; FEMALE; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; UREA BLOOD LEVEL;

EID: 84947488830     PISSN: 11102608     EISSN: 2090911X     Source Type: Journal    
DOI: 10.1016/j.ehj.2014.12.002     Document Type: Article

References (29)

1. Reed M.C., Moscucci M., Smith D.E., et al. The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from blue cross blue shield of michigan cardiovascular consortium (BMC2). J Invasive Cardiol 2010, 22:467-472.
2. Al Badarin F.J., McDonald F.S., Bartholmai B.J., et al. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. CircCardiovascInterv 2010, 3:351-358.
3. From A.M., Bartholmai B.J., Williams A.W., et al. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clinic Proc 2008, 83:1095-1100.
4. Aspelin P., Aubry P., Fransson S.G., et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003, 348:491-499.
5. McCullough P.A. Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis 2008, 51:169-172.
6. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 1996, 335:1001-1009.
7. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:39-43.
8. Morikawa S., Takabe W., Mataki C., et al. Coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002, 9:178-183.
9. Szummer K., Lundman P., Jacobson S.H., et al. Cockcroft-Gault is better than the modification of diet in renal disease study formula at predicting outcome after a myocardial infarction: data from the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Am Heart J 2010, 159:979-986.
10. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 2005, 111:2099-2106.
11. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004, 350:232-238.
12. Gupta R., Birnbaum Y., Uretsky B.F., et al. The renal patient with coronary artery disease. Current concepts and dilemmas. J Am Coll Cardiol 2004, 44:1343-1353.
13. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105(19):2259-2264.
14. Parfrey P.S., Griffiths S.M., Barrett B.J., et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. N Engl J Med 1989, 320:143-153.
15. Toprak O., Cirit M., Bayata S., et al. The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. AnadoluKardiyolDerg 2003, 3:98-103.
16. Liss P., Nygren A., Erikson U., et al. Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int 1998, 53:698-702.
17. Heinrich M.C., Kuhlmann M.K., Grgic A., et al. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005, 235:843-849.
18. McCullough P.A., Wolyn R., Rocher L.L., et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103:368-375.
19. Jo S.H., Koo B.K., Park J.S., et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J 2008, 155(3):499-e1.
20. Toso A., Maioli M., Leoncini M., et al. Usefulness of atorvastatin (80mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010, 105(3):288-292.
21. Bouzas-Mosquera Alberto, Vázquez-Rodríguez José M., Calviño-Santos Ramón, et al. Statin therapy and contrast-induced nephropathy after primary angioplasty. Int J Cardiol 2008, 134(3):430-431.
22. Zhang Bu-Chun, Li Wei-Ming, Ya-Wei Xu, et al. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011, 27(6):851-858.
23. Xinwei J., Xianghua F., Jing Z., et al. Comparison of usefulness of simvastatin 20mg versus 80mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009, 104(4):519-524.
24. Zhao Jing-Lin, Yang Yue-Jin, Zhang Yuan-hui, et al. Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2008, 126(3):435-436.
25. Yoshida Susumu, Kamihata Hiroshi, Nakamura Seishi, et al. Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 2009, 54(2):192-198.
26. Pappy Reji, Stavrakis Stavros, Thomas A., et al. Effect of statin therapy on contrast-induced nephropathy after coronary angiography. Meta-Anal Int J Cardiol 2011, 151(3):348-353.
27. Khanal S., Attallah N., Smith D.E., et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005, 118(8):843-849.
28. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of MYocardial damage during angioplasty-contrast-induced nephropathy] Trial; 1-7, July 2011.
29. Xie H., Ye Y., Shan G., Zhang S., Fang Q., Yang D., et al. Effect of statins in preventing contrast-induced nephropathy: an updated meta-analysis. Coron Artery Dis 2014, [Epub ahead of print].